

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

**INCLUSION AS A CONSTITUENT OF
HANG SENG COMPOSITE INDEX**

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**” or “**IMPACT Therapeutics**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that it has been selected and will be included as a constituent stock of the Hang Seng Composite Index (“**HSCI**”) by Hang Seng Indexes Company Limited, with effect from September 7, 2026.

Upon inclusion as a constituent stock of HSCI, the shares of the Company are expected to meet the inclusion criteria for trading via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect. The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for stock trading and investment between capital market investors in Hong Kong and Chinese Mainland.

The Company believes that its inclusion in the HSCI as a constituent stock demonstrates that international capital markets have recognized the industry standing, operating performance and overall value of the Company. This is anticipated to strengthen trading liquidity in the shares, widen and diversify the base of shareholders, and contribute to sustained growth over the longer term. For further details regarding HSCI, please refer to the relevant index notice(s) published on the website of Hang Seng Indexes Company Limited (<https://www.hsi.com.hk>).

The Company appreciates the continued support from the shareholders and investors.

About IMPACT Therapeutics

Founded in 2009, IMPACT Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients. IMPACT was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on May 13, 2026 (Stock Code: 07630.HK). IMPACT Therapeutics has in-house discovered and developed one of the most comprehensive and advanced SL franchises and is one of only three companies with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1-selective inhibitors worldwide.

IMPACT Therapeutics' core product, senaparib (IMP4297), has already been commercialized, following its approval as 1L maintenance therapy for OC "all-comers" in China in January 2025, and is reimbursable for OC 1L "all-comers" since January 1, 2026. Senaparib also delivered the most favorable PFS outcome among PARP1/2 inhibitors (non head-to-head) for 1L maintenance therapy for OC "all-comers" in China, setting a new benchmark in this class.

IMPACT Therapeutics' major pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.

IMPACT Therapeutics' continued growth is powered by an integrated R&D platform that enables innovation across both small molecules and emerging modalities, including ADCs and degraders, with the identification of PCC from each modality. Additionally, IMPACT Therapeutics has forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of its pipeline and R&D platform.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company may not be able to fully realize the potential of senaparib and successfully advance its clinical development for additional indications as planned. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, August 24, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.